{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-25-000139","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2025-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.793573+00:00","generated_at":"2026-05-20T05:19:28.238043+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Neurocrine CMO Eiry Roberts to step down; Sanjay Keswani named successor June 2, 2025","bullets":["Dr. Eiry Roberts transitions from CMO to Strategic Advisor to the CEO, effective June 2, 2025 through Dec 31, 2025.","Dr. Sanjay Keswani will succeed Dr. Roberts as Chief Medical Officer, effective June 2, 2025.","Dr. Roberts receives annual base salary of $731,400 and target bonus of 60% of base pay in new advisory role.","Outstanding equity awards continue vesting; severance terms substantially unchanged from prior agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-25-000139","json":"https://secwatch.observer/filing/0000914475-25-000139.json","markdown":"https://secwatch.observer/filing/0000914475-25-000139.md","text":"https://secwatch.observer/filing/0000914475-25-000139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000139/0000914475-25-000139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000139/nbix-20250530.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T05:19:28.238043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a5933426c","claim":"Eiry W. Roberts changed role as Strategic Advisor to the CEO at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000139/0000914475-25-000139-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Strategic Advisor to the CEO"}],"fact_type":"executive_change"},{"claim_id":"d6f2976a79","claim":"Sanjay Keswani was appointed as Chief Medical Officer at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000139/0000914475-25-000139-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}